News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

Alzheimer’s disease drug, donanemab, has been approved by India’s drug regulator and is expected to be launched within the ...

Eli Lilly (NYSE:LLY) just landed a meaningful international win after India's drug regulator approved donanemab, the ...

Eli Lilly receives CDSCO approval for donanemab, a new Alzheimer's treatment targeting early symptomatic stages of the ...

Alzheimer’s drug donanemab approved for use by drug regulator, likely to be available in India next year ...

An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still maintained sufficient amyloid reduction in early Alzheimer's disease, the ...

Eli Lilly has received CDSCO approval for donanemab, an Alzheimer's treatment for adults in early symptomatic stages ...

The opinion will now be referred to the European Commission for final regulatory decision on donanemab INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today ...

The National Institute for Health and Care Excellence (NICE) has recommended that donanemab not be approved for use on the NHS on the day that the Medicines and Healthcare products Regulatory Agency ...

Eli Lilly (LLY) announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for donanemab, an injection for intravenous infusion every four ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the ...